Humacyte prices 47,619,048-share follow-on offering at $1.05 each to raise $50 million

Humacyte

Humacyte

HUMA

0.00
  • Humacyte priced an underwritten public offering of 47,619,048 common shares at USD 1.05 each.
  • Gross proceeds expected at USD 50 million, before fees; closing targeted for June 12, 2026.
  • Underwriters hold a 30-day option to buy up to 7,142,857 additional shares at the offering price, less discounts.
  • Net proceeds earmarked for Symvess commercialization, a planned BLA supplement filing for hemodialysis, pipeline development, working capital.
  • Barclays, BTIG, Titan Partners serving as joint book-running managers.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Humacyte Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606102108PRIMZONEFULLFEED9735356) on June 11, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.